CG Oncology said its oncolytic immunotherapy succeeded in a late-stage trial in certain patients with non-muscle invasive bladder cancer, potentially expanding the asset’s market significantly.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Source link







